In a recent research report by Maximize Market Research, the Castrate-resistant Prostate cancer market is expected to surpass US $ 16.2 Bn by the year 2027, from the US $ 9.3 Bn in 2020.
Chemotherapy is one of the best treatment options for Castrate-resistant Prostate Cancer (CRPC), and it is used as the first treatment. Docetaxel (Taxotere) and prednisone are two approved chemotherapy drugs. Second-line treatment for mCRPC patients whose disease progressed after or during docetaxel therapy has been developed as a result of increasing advancements in chemotherapy.
The influence of major market players and an increase in the number of government initiatives aimed at retailers in various regions are anticipated to boost the castrate-resistant prostate cancer market forward. Awareness level of early diagnosis and treatment options, as well as growing adoption for cost-effective and successful treatment strategies, are likely to drive the sales channel, particularly in the APAC and MEA regions. Additionally, Asia Pacific is projected to boost the market of Castrate-resistant prostate cancer. Due to the presence of the key market player, increasing treatment options and amplified Research & Development activities in countries such as China, India, and Japan. As a result, there has been a surge in the development of prostate cancer drugs and therapies. Moreover, clinical trials in developing countries are less expensive than in developed countries. Hence, this factor is likely to fuel market growth.
Europe is estimated to gain significant market share in 2020 owing to the combined efforts of several governments and private institutes, such as the European Organization for Research and Treatment of Cancer (EORTC) and the European Medicines Agency (EMA), to develop unique programs focusing on multiple approaches in drug development. The market for castrate-resistant prostate cancer and health awareness programs to educate individuals about modern medications and advanced therapies is further supporting the market expansion. Despite a huge decline in the sales of products during the initial phase of pandemic spread and lockdown restrictions all over the region, the market is observed to pick up a quick pace for registering a CAGR of almost more than 8.4 %, during the tenure of 2021 – 2027.
The report published by Maximize encompasses the market dynamics, which could affect the market growth of the Market in the region, the Value – Chain Analysis, and the PORTER’s analysis for the Castrate-resistant Prostate Cancer Market at a global level. The study is associated based on major segments and further into sub-segments, Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy) to forecast the market size by value; also includes the analysis of past market dynamics from 2016 – 2019, considering 2020 as the base year.
Lastly, the market research report provides a regional comparison and a complete country-level analysis for the Technology trends, along with the major key players- Gilead Sciences, Inc., Active Biotech, Diagnocure, GlaxoSmithKline, Northwest Biotherapeutics, Millennium Pharmaceuticals, Hologic, Spectrum Pharmaceuticals, Abbott Laboratories, Bayer Healthcare Pharmaceuticals, Sanofi, Johnson & Johnson Services, Inc., Pfizer, Inc., Astellas Pharma, Inc.Bayer AG.
You can browse the market data Tables and Figures spread through a comprehensive research report and in-depth TOC on the “Global Castrate-resistant Prostate Cancer Market.”
Contact:
MAXIMIZE MARKET RESEARCH PVT. LTD.
3rd Floor, Office no. 18.4,
Navale IT Zone Phase-2,
Mumbai -Bangalore bypass highway,
Pune- 18.411018.41
Maharashtra, India
+91 9607195908